Tuesday, March 24, 2015

Good News -- But Unsurprising -- Pembrolizumab (Keytruda®) Is An Effective First Line -- In Melanoma

I'll highlight it here, because it adds to the thesis: Anti PD-1 immuno approaches are the wave of the future -- in many, many cancers.

Good news, for Kenilworth, and cancer patients. The high burden disease states await. Here's the Merck presser:

. . . .[Merck] today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating Keytruda® (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the study’s independent Data Monitoring Committee. . . .

Enjoy a productive Tuesday now, one and all.

No comments: